Table 3. Levels of immune checkpoint inhibitors on immune cells in patients with BD, MD and controls (mean ± SD).

Immune checkpoint	BD (n = 23)	MD (n = 22)	HC (n = 20)	P1	P2	P3	P4
T cell total TIM-3†	6.43 ± 2.62	7.91 ± 4.63	6.55 ± 2.20	0.920	0.243	0.219	0.378
T cell total PD-1†	16.6 ± 4.55	22.55 ± 8.74	16.65 ± 4.94	0.985	0.072	0.083	0.160
CD4+TIM-3+△	3.68 ± 2.12	3.61 ± 1.94	3.08 ± 1.04	0.681	0.668	0.856	0.882
CD4+PD-1+†	19.70 ± 9.70	19.50 ± 12.01	16.17 ± 5.55	0.343	0.459	0.966	0.573
CD8+TIM-3+†	11.45 ± 4.15	10.22 ± 4.90	7.81 ± 2.44	0.011*	0.082	0.379	0.034*
CD8+PD-1+†	16.19 ± 5.30	19.10 ± 11.59	19.03 ± 6.80	0.385	0.986	0.488	0.644
CD14+TIM-3+†	84.42 ± 19.75	81.69 ± 15.68	83.85 ± 11.41	0.920	0.692	0.648	0.885
CD14+PD-1+△	9.78 ± 8.97	4.72 ± 3.02	7.24 ± 4.14	1.000	0.206	0.350	0.465
CD14+PD-L1+△	5.51 ± 5.86	7.89 ± 9.33	3.56 ± 2.49	0.913	0.079	0.318	0.257
CD14+PD-L2+†	24.90 ± 10.84	30.74 ± 18.33	36.74 ± 14.29	0.029*	0.242	0.291	0.088

^*P < 0.05 (two-tailed). P₁: BD and HC; P₂: MD and HC; P₃: BD and MD; P₄: BD, MD and HC.

^†One-way ANOVA test; ^ΔKruskall–Wallis test.